In8bio, INC 8-K filings

IN8bio announced second quarter 2026 financial results, showcasing advancements in its gamma delta T cell engager platform and positive clinical data for its glioblastoma treatment.

IN8bio, Inc. has entered into a new Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC for an at-the-market offering program, while simultaneously terminating a previous agreement with Cantor Fitzgerald & Co.

IN8bio announced first quarter 2026 financial results, highlighting progress in its gamma-delta T cell therapies and T cell engager platform, with encouraging glioblastoma data and upcoming R&D Day.

IN8bio announced positive full-year 2025 financial results, durable survival improvements in glioblastoma trials, and a strengthened financial position extending its cash runway into the first half of 2027.

IN8bio, Inc. announced the resignation of director Alan S. Roemer and the appointment of Jeremy Graff as Interim Chair of the Board, effective February 28, 2026.

IN8bio, Inc. announced the appointment of Chief Operating Officer Kate Rochlin as President, effective February 4, 2026.

IN8bio, Inc. announced a private placement to raise an initial $20.1 million, with an option for an additional $20.1 million contingent on a key clinical milestone and stock performance.

IN8bio, Inc. reported positive clinical data from its INB-200 and INB-400 trials for glioblastoma, showing extended progression-free and overall survival.

IN8bio, a clinical-stage biopharmaceutical company, announced its third quarter 2025 financial results and provided updates on its gamma-delta T cell therapy pipeline, including new preclinical data for INB-619 and expansion of the INB-100 trial.

IN8bio announced new preclinical data for its INB-619 T cell engager, demonstrating deep B cell depletion with a potentially superior safety profile for autoimmune diseases.

IN8bio announced positive Q2 2025 financial results and significant clinical milestones, including a glioblastoma patient achieving over four years of progression-free survival with INB-200.

IN8bio, Inc. announced it has received formal notification from The Nasdaq Stock Market LLC confirming compliance with the minimum bid price requirement, effectively closing the matter.

IN8bio, Inc. has announced a 1-for-30 reverse stock split, effective June 5, 2025, to consolidate its common stock and adjust its share price.

IN8bio, Inc. announced positive long-term Phase 1 clinical data for its INB-200 therapy in newly diagnosed glioblastoma multiforme, demonstrating a significant extension in progression-free survival compared to standard of care.

IN8bio, Inc. held its annual meeting on May 8, 2025, electing three directors, ratifying the selection of CohnReznick LLP as its independent auditor, and approving a reverse stock split.

IN8bio announces positive Q1 2025 financial results and highlights, including durable remissions in AML patients treated with INB-100 and advancements in their INB-600 T cell engager platform.

IN8bio's new gamma-delta T cell engager (gd-TCE) platform demonstrates significant gd T cell expansion and potent anti-cancer activity in preclinical studies, potentially offering a safer alternative to conventional CD3-based approaches.

IN8bio, Inc. has entered into agreements to amend its Securities Purchase Agreement and induce the exercise and exchange of warrants, expecting to receive approximately $1.9 million in gross proceeds.

IN8bio highlights durable remissions in cancer trials and strategic pipeline optimization in its fourth quarter and full-year 2024 report.

Travis Whitfill, a member of IN8bio's Board of Directors, has resigned effective May 9, 2025.

IN8bio announces a new gamma-delta T cell engager platform, INB-600, designed to enhance T cell expansion and target B cells for oncology and autoimmune applications, with its lead candidate INB-619 showing promising preclinical results.

IN8bio reports updated data from its Phase 1 trial of INB-100, showing 100% complete remission in acute myeloid leukemia (AML) patients with a median follow-up of 20.1 months.

IN8bio, Inc. received an extension from Nasdaq to regain compliance with the minimum bid price rule and announced the date for its 2025 Annual Meeting of Stockholders.

IN8bio's INB-100 therapy shows continued progression-free survival in leukemia patients, with durable remissions and no relapses observed in AML patients after a median follow-up of 19.7 months.

IN8bio reports encouraging clinical data from its Phase 1 trial of INB-200, showing durable remissions and immune cell infiltration in glioblastoma patients.

IN8bio announced positive clinical trial results for its INB-100 therapy, along with a $11.6 million private placement to extend its cash runway into 2026.

IN8bio, Inc. has entered into a securities purchase agreement for a private placement, raising approximately $12.4 million and amending existing warrants.

IN8bio's Chief Medical Officer, Trishna Goswami, has stepped down, effective September 6, 2024, with a severance agreement in place.

IN8bio executives agree to salary reductions effective September 1, 2024, in exchange for enhanced severance and change of control benefits.

IN8bio is prioritizing its clinical pipeline, focusing on INB-100 for AML, and reducing its workforce by 49% to conserve cash.